FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Fiche publication


Date publication

décembre 2018

Journal

The New England journal of medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher, Pr CONROY Thierry, Pr RAT Patrick


Tous les auteurs :
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB,

Résumé

Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer.

Mots clés

Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Chemotherapy, Adjuvant, Deoxycytidine, adverse effects, Disease-Free Survival, Drug Combinations, Female, Fluorouracil, adverse effects, Humans, Leucovorin, adverse effects, Lung Diseases, Interstitial, chemically induced, Male, Middle Aged, Organometallic Compounds, adverse effects, Pancreatic Neoplasms, drug therapy, Proportional Hazards Models, Prospective Studies

Référence

N. Engl. J. Med.. 2018 Dec 20;379(25):2395-2406